Quick Stats for GLP-1 Diabetes Treatment Drugs Market GLP-1 Diabetes Treatment Drugs Market Value (2025): USD 6,556.5 million GLP-1 Diabetes Treatment Drugs Market Forecast Value (2035): USD 62,543.2 million GLP-1 Diabetes Treatment Drugs Market Forecast CAGR: 25.3% Leading Drug Type in GLP-1 Diabetes Treatment Drugs Market: Liraglutide (35.5%) Key Growth Regions in GLP-1 Diabetes Treatment Drugs Market: Asia Pacific, North America, and Europe Top Key Players in GLP-1 Diabetes Treatment Drugs Market: Eli Lilly, Sanofi, Novo Nordisk, Hanmi Pharmaceutical Co., Boehringer Ingelheim, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline (GSK), Ganli Pharmaceuticals, Tonghua Dongbao, Shanghai Renhui Biopharmaceuticals Co., Ltd., Huadong Medicine, Page Biopharmaceuticals, Jiangsu Hausen Pharmaceuticals Group Co., Ltd
12 Fiber Friends: For Digestion and Fullness Fiber plays a multifaceted role in supporting health during GLP-1 therapy
The patient was started on semaglutide for her diabetes approximately 10 months prior to presentation
According to the study, researchers analyzed electronic health records from nearly 40,000 adults with type 2 diabetes who started GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors between 2019 and 2024
With appropriate clinical support, GLP-1s may work for many patients
Users do not need to fully understand the category science to see the use case